后COVID条件(PCC)是源于COVID-19的病理,并研究其病理生理学,诊断,治疗至关重要。神经炎症导致这种疾病最常见的表现,包括头痛,疲劳,失眠,抑郁症,焦虑,在其他人中。目前,没有具体的管理建议;然而,考虑到炎症成分涉及细胞因子和自由基,必须对这些疾病进行治疗以减轻当前症状,并提供神经保护以降低长期神经退行性疾病的风险。已经表明,大麻在其他病理中具有免疫调节和抗氧化功能的化合物。因此,探索这种方法可以为PCC提供可行的治疗选择,这就是这次审查的目的。这篇综述涉及对包括PubMed在内的专业数据库的详尽搜索,PubChem,ProQuest,EBSCO,Scopus,科学直接,WebofScience,和临床试验。植物大麻素,包括大麻二酚(CBD),大麻酚(CBG),和Delta-9-四氢大麻酚(THC),表现出显著的抗氧化和抗炎特性,并已被证明是治疗神经炎性疾病的有效方法。这些化合物可以是单独或与其他抗氧化剂或疗法组合的PCC的有前途的佐剂。PCC对神经健康提出了重大挑战,神经炎症和氧化应激在其发病机制中起着核心作用。抗氧化剂疗法和基于大麻素的方法代表了减轻不良反应的研究和治疗的有希望的领域。但还需要进一步的研究。
The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, and treatment is crucial. Neuroinflammation causes the most common manifestations of this disease including headaches, fatigue, insomnia, depression, anxiety, among others. Currently, there are no specific management proposals; however, given that the inflammatory component involves cytokines and free radicals, these conditions must be treated to reduce the current symptoms and provide neuroprotection to reduce the risk of a long-term neurodegenerative disease. It has been shown that cannabis has compounds with immunomodulatory and antioxidant functions in other pathologies. Therefore, exploring this approach could provide a viable therapeutic option for PCC, which is the purpose of this review. This review involved an exhaustive search in specialized databases including PubMed, PubChem, ProQuest, EBSCO, Scopus, Science Direct, Web of Science, and Clinical Trials. Phytocannabinoids, including cannabidiol (CBD), cannabigerol (CBG), and Delta-9-tetrahydrocannabinol (THC), exhibit significant antioxidative and anti-inflammatory properties and have been shown to be an effective treatment for neuroinflammatory conditions. These compounds could be promising adjuvants for PCC alone or in combination with other antioxidants or therapies. PCC presents significant challenges to neurological health, and neuroinflammation and oxidative stress play central roles in its pathogenesis. Antioxidant therapy and cannabinoid-based approaches represent promising areas of research and treatment for mitigating adverse effects, but further studies are needed.